Tuesday, July 25, 2017

Data Published in The Lancet Shows High Efficacy at 96 Weeks for First Investigational Two-Drug, Long-Acting Injectable HIV Regimen



CORK, Ireland-Monday, July 24th 2017 [ ME NewsWire ]

- Long-term data from the Phase 2b LATTE-2 study demonstrated comparable antiviral activity to daily, oral 3-drug combination -

- Data presented as an oral late breaker at the 9th International AIDS Society Conference, 23-26 July 2017, Paris, France -

(BUSINESS WIRE)-- Janssen Sciences Ireland UC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) today announced that a regimen of two investigational long-acting, injectable formulations of HIV medicines —Janssen’s rilpivirine and ViiV Healthcare’s cabotegravir — given together every 4 or 8 weeks was as effective as 3-drug oral antiretroviral therapy (ART) at maintaining HIV-1 viral suppression through 96 weeks (HIV-1 RNA <50 copies per mL). Results published in The Lancet show that if approved, this first two-drug, long-acting regimen could offer a highly effective suppressive maintenance therapy for people living with HIV.

Viral suppression was achieved in 94 percent of those (n=108) receiving injections every eight weeks, warranting further investigation. Virologic response was also achieved by 87 percent (n=100) of those receiving injections every four weeks versus 84 percent (n=47) receiving oral ART therapy. In an unprecedented outcome, no virologic non-responders to the long-acting regimen were observed in the four-week group, as determined by the stringent FDA snapshot algorithm. Few virologic non-responders were seen in the eight-weekly group (n=5 [4%]). These results highlighted that the two-drug, long-acting regimen offered durability of virologic response throughout almost 2 years of treatment.

“Results published in The Lancet strengthen the evidence that a two-drug, long-acting regimen may offer an effective and acceptable alternative for people who have achieved viral suppression but struggle with daily, oral regimens to control their HIV,” said Paul Stoffels M.D., Chief Scientific Officer, Johnson & Johnson. “Non-adherence to treatment remains a challenge for many people living with HIV and one of the main drivers of resistance to HIV medicines. Our hope is to make HIV treatment manageable for all by developing innovative solutions like long-acting regimens.”

In LATTE-2, patients with HIV-1 viral suppression on oral medication (cabotegravir plus abacavir/lamivudine) were randomized 2:2:1 to long-acting injections every four or eight weeks, or to daily oral cabotegravir taken with abacavir and lamivudine.

High satisfaction was reported in the study by those receiving the two-drug, long-acting regimen, which suggests it may provide a preferred alternative for many people living with HIV who may not wish to consider taking life-long oral therapy. The data are based on the observed case data set of subjects who completed questionnaires at week 48 and week 96.

The two-drug, long-acting regimen was generally well tolerated, with no drug-related serious adverse events and few adverse event-related withdrawals. While injection-site reactions (ISRs) were common (four-weekly group, 97% of patients; eight-weekly group, 96% of patients), they were transient in nature, and mild or moderate in severity. The long-term acceptability of administering chronic intramuscular injections to patients was also demonstrated in LATTE-2, with very few withdrawals resulting from ISRs (two patients [<1%]), through 96 weeks.

The most commonly reported non-ISR adverse events were nasopharyngitis (four-weekly group, 34%; eight-weekly group, 30%; oral cabotegravir plus abacavir/lamivudine groups, 39%), diarrhea (four-weekly group, 28%; eight-weekly group, 23%; oral cabotegravir plus abacavir/lamivudine group, 20%), and headache (four-weekly group, 23%; eight-weekly group, 25%; oral cabotegravir plus abacavir/lamivudine group, 25%).

Two global Phase 3 switch studies, FLAIR (First Long-Acting Injectable Regimen) and ATLAS (Antiretroviral Therapy as Long-Acting Suppression), are currently examining the safety and efficacy of four weekly dosing with the two-drug, injectable regimen. For more information on the clinical trials, please visit: www.clinicaltrials.gov.

These results will be presented in an oral abstract session at the 9th International AIDS Society Conference on HIV Science (IAS 2017) at 12:00 on Monday 24 July 2017. Please visit jnj.com/HIV for additional details on the breadth of science being presented by Johnson & Johnson companies and its partners.

###

About the LATTE 2 clinical trial (NCT02120352)

LATTE-2 is an ongoing Phase 2b, multicenter, parallel group, and open-label study which recruited ART-naïve HIV-infected adults. Enrolled patients who had a plasma HIV-1 RNA, <50 c/mL during 20-week Induction Period (IP) with daily oral cabotegravir (CAB) 30 mg plus abacavir/lamivudine 600 mg/300 mg were randomized 2:2:1 to intramuscular injections every 4 weeks (long-acting cabotegravir 400 mg plus rilpivirine 600 mg; two 2-mL injections) or every 8 weeks (long-acting cabotegravir 600 mg plus rilpivirine 900 mg; two 3-mL injections), or to continue receiving three-drug, oral ART in the Maintenance Period (MP). The primary endpoints evaluated antiviral activity by FDA snapshot algorithm, protocol defined virologic failure, and safety at 32 weeks in the maintenance period. Antiviral activity, protocol-defined virologic failures and safety events through 96 weeks for the maintenance population were key secondary endpoints.

About cabotegravir

Cabotegravir is an investigational integrase strand transfer inhibitor (INSTI) and is not approved by regulatory authorities anywhere in the world. Cabotegravir is being developed by ViiV Healthcare as a long-acting, nanosuspension formulation for intramuscular injection for the treatment and prevention of HIV.

About EDURANT® (Rilpivirine)

EDURANT® (rilpivirine) is a prescription HIV medicine that is used with other antiretroviral medicines to treat Human Immunodeficiency Virus-1 (HIV-1) in patients:

    Who have never taken HIV medicines before, and
    Who have an amount of HIV in their blood (called “viral load”) that is no more than 100,000 copies/mL. Your healthcare professional will measure your viral load.

EDURANT® should be taken in combination with other HIV medicines. Your healthcare professional will work with you to find the right combination of HIV medicines.

It is important that you remain under the care of your healthcare professional during treatment with EDURANT®.

EDURANT® is not recommended for patients less than 12 years of age.

EDURANT® does not cure HIV infection or AIDS. You should remain on your HIV medications without stopping to ensure that you control your HIV infection and decrease the risk of HIV-related illnesses. Ask your healthcare professional about how to prevent passing HIV to other people.

Please read Important Safety Information below, and talk to your healthcare professional to learn if EDURANT® is right for you.

Important Safety Information

Can EDURANT® be taken with other medicines?

EDURANT® may affect the way other medicines work and other medicines may affect how EDURANT® works and may cause serious side effects. If you take certain medicines with EDURANT®, the amount of EDURANT® in your body may be too low and it may not work to help control your HIV infection, and the HIV virus in your body may become resistant to EDURANT® or other HIV medicines that are like it. To help get the right amount of medicine in your body, you should always take EDURANT® with a meal. A protein drink alone does not replace a meal.

Do not take EDURANT® if:

    Your HIV infection has been previously treated with HIV medicines
    You are taking any of the following medicines:
        Anti-seizure medicines: carbamazepine (Carbatrol®, Equetro®, Tegretol®, Tegretol-XR®, Teril®, Epitol®), oxcarbazepine (Trileptal®), phenobarbital (Luminal®), phenytoin (Dilantin®, Dilantin-125®, Phenytek®).
        Anti-tuberculosis (anti-TB) medicines: rifampin (Rifater®, Rifamate®, Rimactane®, Rifadin®), rifapentine (Priftin®) Proton pump inhibitor (PPI) medicine for certain stomach or intestinal problems: esomeprazole (Nexium®, Vimovo®), lansoprazole (Prevacid®), omeprazole (Prilosec®, Zegerid®), pantoprazole sodium (Protonix®), rabeprazole (Aciphex®).
        More than 1 dose of the steroid medicine dexamethasone or dexamethasone sodium phosphate.
        St. John’s wort (Hypericum perforatum).
    Especially tell your doctor if you take:
        Rifabutin (Mycobutin®), a medicine to treat some bacterial infections). Talk to your doctor or pharmacist about the right amount of EDURANT® you should take if you also take rifabutin.
        Medicines used to treat HIV.
        An antacid medicine that contains aluminum, magnesium hydroxide, or calcium carbonate. Take antacids at least 2 hours before or at least 4 hours after you take EDURANT®.
        Medicines to block acid in your stomach, including cimetidine (Tagamet®), famotidine (Pepcid®), nizatidine (Axid®), or ranitidine hydrochloride (Zantac®). Take these medicines at least 12 hours before or at least 4 hours after you take EDURANT®.
        Any of these medicines (if taken by mouth or injection): clarithromycin (Biaxin®), erythromycin (E-Mycin®, Eryc®, Ery-Tab®, PCE®, Pediazole®, Ilosone®), fluconazole (Diflucan®), itraconazole (Sporanox®), ketoconazole (Nizoral®), methadone (Dolophine®), posaconazole (Noxafil®), telithromycin (Ketek®), voriconazole (Vfend®).

This is not a complete list of medicines. Before starting EDURANT®, be sure to tell your healthcare professional about all the medicines you are taking or plan to take, including prescription and nonprescription medicines, vitamins, and herbal supplements.

Before taking EDURANT®, also tell your healthcare professional if you have had or currently have liver problems (including hepatitis B or C), have ever had a mental health problem, are pregnant or planning to become pregnant, or breastfeeding. It is not known if EDURANT® will harm your unborn baby.

You and your healthcare professional will need to decide if taking EDURANT® is right for you.

Do not breastfeed if you are taking EDURANT®. You should not breastfeed if you have HIV because of the chance of passing HIV to your baby.

What are the possible side effects of EDURANT®? EDURANT® can cause serious side effects including:

    Severe skin rash and allergic reactions. Call your doctor right away if you get a rash. Stop taking EDURANT® and seek medical help right away if you get a rash with any of the following symptoms: severe allergic reaction causing swelling of the face, eyes, lips, mouth, tongue, or throat (which may lead to difficulty swallowing or breathing); mouth sores or blisters on your body; inflamed eye (conjunctivitis); fever; dark urine; or pain on the right side of the stomach area (abdominal pain).
    Depression or mood changes. Tell your doctor right away if you have any of the following symptoms: feeling sad or hopeless, feeling anxious or restless, have thoughts of hurting yourself (suicide), or have tried to hurt yourself.
    Liver problems. People with a history of hepatitis B or C virus infection or who have certain liver function test changes may have an increased risk of developing new or worsening liver problems during treatment. Liver problems were also reported during treatment in some people without a history of liver disease. Your healthcare professional may need to do tests to check liver function before and during treatment.
    Changes in body shape or body fat have been seen in some patients taking HIV medicines. The exact cause and long-term health effects of these conditions are not known.
    Changes in your immune system (immune reconstitution syndrome).
    Your immune system may get stronger and begin to fight infections. Tell your healthcare professional right away if you start having any new symptoms of infection.
    Other common side effects of EDURANT® include depression, headache, trouble sleeping (insomnia), and rash.

This is not a complete list of all side effects. If you experience these or other symptoms, contact your healthcare professional right away. Do not stop taking EDURANT® or any other medications without first talking to your healthcare professional.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088. You may also report side effects to Janssen Products, LP at 1-800-JANSSEN (1-800-526-7736).

Please see full Product Information for more details.

About Janssen

At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com and follow us at @JanssenGlobal.

Cautions Concerning Forward-Looking Statements

This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding development of potential preventive and treatment regimens for HIV. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of the Janssen Pharmaceutical Companies and Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new indications and therapeutic combinations; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behaviour and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the year ended January 1, 2017, including under “Item 1A Risk Factors,” its most recently filed Quarterly Report on Form 10-Q, including in the section captioned “Cautionary Note Regarding Forward-Looking Statements,” and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.





View source version on businesswire.com: http://www.businesswire.com/news/home/20170724005449/en/

Contacts

Janssen
MEDIA CONTACTS:
Ronan Collins
+47 488 425 00
rcollin5@its.jnj.com
or
Katie Buckley
+44 7971 956 179
kbuckle8@its.jnj.com
or
Gavin Hart
+1 917 686 9221
Ghart9@its.jnj.com
or
INVESTOR RELATIONS:
Lesley Fishman
+1 732-524-3922
or
Joseph J. Wolk
+1 732-524-1142


Permalink : http://me-newswire.net/news/4297/en

Calvin Klein, Inc. annonce le lancement de sa campagne publicitaire mondiale portant sur la collection Automne 2017 CALVIN KLEIN 205W39NYC

Image not foundFALL 2017 CALVIN KLEIN 205W39NYC GLOBAL ADVERTISING CAMPAIGN (Photo: © 2017 Willy Vanderperre)NEW YORK -Mardi 25 Juillet 2017 [ ME NewsWire ]

(BUSINESS WIRE)--Calvin Klein, Inc., une filiale à cent-pour-cent de PVH Corp. [NYSE: PVH], a annoncé aujourd'hui le lancement de sa campagne mondiale publicitaire dont fait l'objet la collection Automne 2017CALVIN KLEIN 205W39NYC . Cette campagne mondiale de publicité multimédia représente les débuts de la collectionCALVIN KLEIN 205W39NYC réalisée par le Directeur de la Création Raf Simons.

Cette campagne, remarquable sur le plan visuel, dont les prises de vue ont été réalisées par le photographeWilly Vanderperre, présente une série de 22 mannequins, photographiés avec, en toile de fond, une série de panneaux comportant des images de la campagne publicitaire de la saison précédente, American Classics de CALVIN KLEIN. Les panneaux de la précédente campagne publicitaire - qui incluent des oeuvres de l'artiste Andy Warhol – ont été érigés dans le désert californien dans les jours précédant la prise de vues. Cette campagne est une recherche sur l'art et les artifices, le réel et l'imaginaire, le monde recherché de la haute couture combiné à un sentiment du quotidien. Enfin, la campagne explore la vision cinématographique et romantique de l'Amérique que peut avoir un étranger, une sorte de monde imaginaire devenu réel pour le Directeur de la Création Raf Simons et le Directeur artistique Pieter Mulier.

Avec plus de 850 millions d'impressions prévues dans 22 marchés internationaux à l'aide d'une combinaison de médias intégrés, cette campagne publicitaire tirera parti de l'évolution de CALVIN KLEIN sous la direction de Raf Simons. La marque sera largement mise en vedette dans le monde entier, dans des publications de mode et de style de vie, dans les éditions du mois de septembre axées sur la mode. La réappropriation de la campagne à succèsAmerican Classics prendra vie dans des affiches grand format d'extérieur à impact élevé, dans des lieux clés tels New York, Paris, Bruxelles, la Chine, la Corée et Hong Kong.

La collection Automne 2017 CALVIN KLEIN 205W39NYC présentée dans le cadre de cette campagne est un mélange d'uniformes de fanfare, de vêtements de protection en plastique, de confection Power Broker, de courtepointes anciennes faites à la main, de vêtements de travail et de vêtements de style Western. La ligne de prêt à porter comprend également le lancement de CALVIN KLEIN JEANS ESTABLISHED 1978, une nouvelle ligne Denim griffée qui sera incluse dans la collectionCALVIN KLEIN 205W39NYC . Toutes les pièces de la ligne sont estampillées d'un motif exclusif : une silhouette féminine inspirée de la photographie emblématique de l'actrice Brooke Shileds prise par Richard Avedon pour Calvin Klein Jeans en 1981. Cette image mémorable de la campagne publicitaire a été publiée peu de temps après le lancement de la marqueCalvin Klein Jeans et du concept de jeans griffés – ainsi, CALVIN KLEIN JEANS ESTABLISHED 1978 célèbre à la fois l'histoire de la marque et son avenir.

Calvin Klein est une marque mondiale mettant en valeur un style de vie audacieux, des idéaux progressistes, offrant un look esthétique souvent minimal et plein de séduction. Nous cherchons à faire vibrer et à inspirer notre public tout en utilisant l'imagerie provocante de modèles frappants pour enflammer les sens.

Fondée en 1968 par Calvin Klein et son partenaire d'affaires Barry Schwartz, notre société s'est bâtie une réputation en qualité de leader de la mode américaine, grâce à ses modèles de vêtements épurés, esthétiques et novateurs. Les ventes au détail mondiales des produits de la marque Calvin Klein ont dépassé les 8 milliards d'USD en 2015 et ont été distribuées dans [plus de] 110 pays. Calvin Klein emploie plus de 10.000 collaborateurs à travers le monde. La société a été acquise par PVH Corp. en 2003.

Grâce à un histoire de plus de 130 ans, PVH Corp. s’est illustrée dans le développement des marques et des entreprises auxquelles il insuffle le riche patrimoine américain ; d’où sa place de choix au rang des plus grandes sociétés mondiales du secteur du vêtement. Nous avons plus de 30.000 associés, répartis dans plus de 40 pays, qui ont généré plus de 8 milliards de recettes. Nous possédons les marques emblématiques Calvin Klein, Tommy Hilfiger, Van Heusen, IZOD, ARROW, Speedo*, Warner’s et Olga sous lesquelles nous commercialisons divers produits, et d’autres marques détenues et agréées aux niveaux national et international.

* La marque Speedo est sous licence à perpétuité de Speedo International Ltd pour l’Amérique du Nord et les Caraïbes.

REDACTION: CALVIN KLEIN 205W39NYC

IMAGES: © 2017 Willy Vanderperre

MEDIAS SOCIAUX: facebook.com/calvinklein; calvinklein.tumblr.com; google.com/+calvinklein; youtube.com/calvinklein; twitter.com/calvinklein; instagram.com/calvinklein; pinterest.com/calvinklein
snapchat: calvinklein
brand handle: @calvinklein

Le texte du communiqué issu d’une traduction ne doit d’aucune manière être considéré comme officiel. La seule version du communiqué qui fasse foi est celle du communiqué dans sa langue d’origine. La traduction devra toujours être confrontée au texte source, qui fera jurisprudence.

Contacts

Calvin Klein, Inc.
Alexandra Wagner, 212-292-9794
Vice-présidente sénior, Communications d'entreprise
alexandrawagner@ck.com
ou
Amanda Peña, 212-292-9223
Directrice, Communications d'entreprise
amandapena@ck.com

Permalink : http://www.me-newswire.net/fr/news/4299/fr

شركة كالفن كلاين تعلن عن الحملة الإعلانية العالمية "كالفن كلاين ٢٠٥ دبليو ٣٩ إن واي سي" لخريف 2017

Image not found
FALL 2017 CALVIN KLEIN 205W39NYC GLOBAL ADVERTISING CAMPAIGN (Photo: © 2017 Willy Vanderperre)نيويورك -يوم الإثنين 24 يوليو 2017 [ إم إي نيوز واير ]

(بزنيس واير): أعلنت اليوم شركة "كالفن كلاين" المملوكة بالكامل من قِبل شركة "بيه في إتش" (المدرجة في بورصة نيويورك تحت الرمز NYSE: PVH) عن إطلاق حملة "كالفن كلاين ٢٠٥ دبليو ٣٩ إن واي سي" الإعلانية العالمية متعددة الوسائط لخريف العام 2017. تشمل الحملة العرض الأول لمجموعة "كالفن كلاين "٢٠٥ دبليو ٣٩ إن واي سي" من "كالفن كلاين" للمصمم والمدير الإبداعي راف سيمونز.

شاركت في الحملة الملفتة للأنظار والتي قام بتصويرها المصور ويلي فاندربير مجموعة من 22 عارضاً وعارضة أزياء موزّعين أمام سلسلة من اللوحات الإعلانية التي تمثّل صوراً من حملة الموسم الفائت لـ"كالفن كلاين" التي كانت مخصصة للملابس الأمريكية الكلاسيكية. وقد وُضعت اللوحات الإعلانية من الحملة السابقة - والتي تتضمن أعمالاً نفذتها الفنانة آندي وارهول - في صحراء كاليفورنيا قبل أيام من بدء جلسة التصوير. وتشكّل الحملة دراسة في الفن والبراعة والحقيقة والخيال، ولعالم الملابس الراقية المتكلّف الممزوج بلمسة من الحياة اليومية. وفي النهاية، تستكشف الحملة النظرة الخارجية السينمائية والرومنسية لأمريكا، وهو عالم من الأحلام التي أصبحت واقعاً بالنسبة إلى الرئيس التنفيذي لشؤون الإبداع راف سيمونز والمدير الإبداعي بيتر موليير.

وستحقق هذه الحملة، التي تتضمن أكثر من 850 مليون ظهور عبر 22 سوقاً عالمياً ومن خلال مزيج متكامل من الوسائل الإعلامية، التطور المستمر لـشركة "كالفن كلاين" تحت إدارة سيمونز. كما ستظهر العلامة التجارية بشكل موسع في كافة المجلات والمنشورات الخاصة بالأزياء وأسلوب الحياة حول العفي الأعداد الخاصة بالموضة التي تصدر في شهر سبتمبر. سيعاد تخصيص الحملة الناجحة للملابس الأمريكية الكلاسيكية بعنوان "أميريكان كلاسيكس" بحجم كبير وتأثير قوي في الهواء الطلق في مواقع رئيسية مثل نيويورك وباريس وبروكسل والصين وكوريا وهونغ كونغ.

وتشكل مجموعة "كالفن كلاين ٢٠٥ دبليو ٣٩ إن واي سي" لخريف العام 2017 التي تتضمنها الحملة مزيجاً من الملابس الموحدة للفرق الموسيقية وملابس الحماية المكسوة بالبلاستيك وبذلات صانعي القرار المفصلة والخياطة الحرفية القديمة وملابس العمل والملابس ذات أسلوب الوسترن. وتشمل المجموعة أيضاً إطلاق "كالفن كلاين جينز إستابلشد 1978"، وهي مجموعة جديدة من الملابس المصنوعة من قماش "الدنيم" القطني المتين الشهير والتي ستندرج ضمن قسم أعمال "كالفن كلاين ٢٠٥ دبليو ٣٩ إن واي سي". تجدر الإشارة إلى أن كافة القطع ضمن المجموعة مزيّنة برقعة حصرية تحمل صورة ظلّية مستوحاة من صورة ريتشارد أفيدون الشهيرة للممثلة بروك شيلدز التي كانت نجمة إعلان "كالفن كلاين جينز" في العام 1981. وكانت صورة الحملة الشهيرة قد ظهرت للمرة الأولى بعد وقت قصير من إطلاق العلامة التجارية "كالفن كلاين جينز" وفكرة ملابس الجينز الشهيرة – بهذه الطريقة، تحتفل "كالفن كلاين جينز إستابلشد 1978" بتاريخ العلامة التجارية ومستقبلها في الوقت نفسه.

إنّ "كالفن كلاين" هي العلامة التجارية العالمية لأسلوب حياة التي تجسّد الجرأة والمثل المتدرجة، وجمالية جذابة غير متكلّفة . نسعى في "كالفن كلاين" إلى إثارة حماسة عملائنا وإلهامهم باعتماد صور مثيرة وتصاميم جذابة لإثارة حواسهم.

ومنذ تأسيس الشركة في العام 1968 من قبل كالفن كلاين وشريكه التجاري باري شوارتز، استطعنا أن نبني سمعتنا كشركة رائدة في مجال الأزياء الأمريكية من خلال التصاميم المبتكرة والجمالية الأنيقة. وقد تجاوزت مبيعات التجزئة العالمية للمنتجات التي تحمل علامة "كالفن كلاين" التجارية 8 مليار دولار أمريكي في عام 2015، وتم توزيعها في [أكثر] من 110 دولة. ويعمل لدى "كالفن كلاين" أكثر من 10 آلاف موظف حول العالم. تم الاستحواذ على الشركة من قبل شركة "بيه في إتش" في العام 2003.

وامتازت "بي في إتش"، عبر تاريخها الممتد على مدى 130 عاماً، بتنمية علامات تجارية وشركات تتمتع بتراث أمريكي غني، لتصبح إحدى أكبر شركات الأزياء في العالم. ويعمل لدى الشركة أكثر من 30 ألف موظف في أكثر من 40 دولةً، وتحقق عائدات تفوق 8 مليار دولار أمريكي. كما نمتلك العلامات التجارية الشهيرة "كالفن كلاين"، و"تومي هيلفيجر"، و"فان هوزن"، و"آيزود"، و"آرو"، و"سبيدو"*، و"وارنرز" و"أولغا،" ونقوم بتسويق مجموعة متنوعة من المنتجات تحت هذه العلامات التجارية بالإضافة إلى علامات تجارية مملوكة أو مرخصة معروفة على الصعيدين المحلي والدولي.

*العلامة التجارية "سبيدو" مرخصة في أمريكا الشمالية ومنطقة البحر الكاريبي لمدى الحياة من قبل شركة "سبيدو إنترناشونال" المحدودة.

تم التحرير من قبل: "كالفن كلاين" 205W39NYC

الصورة: © 2017 Willy Vanderperre

سوسائل التواصل الاجتماعي: "فيسبوك": facebook.com/calvinklein؛

"تمبلر": calvinklein.tumblr.com؛

"جوجل بلاس": google.com/+calvinklein؛

"يوتيوب": youtube.com/calvinklein؛

"تويتر": twitter.com/calvinklein؛

"إنستغرام": instagram.com/calvinklein؛

"بينتريست": pinterest.com/calvinklein؛

"سناب تشات": calvinklein.

وسم العلامة التجارية: @calvinklein.



يمكنكم الاطلاع على معرض الصور/الوسائط المتعددة عبر الرابط الإلكتروني التالي: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=51593752&lang=en.



إن نص اللغة الأصلية لهذا البيان هو النسخة الرسمية المعتمدة. أما الترجمة فقد قدمت للمساعدة فقط، ويجب الرجوع لنص اللغة الأصلية الذي يمثل النسخة الوحيدة ذات التأثير القانوني.

Contacts

شركة "كالفن كلاين"

ألكساندرا واجنر

نائب الرئيس الأول لشؤون الاتصالات المؤسسية

هاتف: 2122929794

البريد الإلكتروني: alexandrawagner@ck.com

أو

أمادا بينيا

مديرة الاتصالات المؤسسية

هاتف: 2122929223

البريد الإلكتروني: amandapena@ck.com

الرابط الثابت : http://www.me-newswire.net/ar/news/4299/ar

Calvin Klein, Inc. Announces Fall 2017 CALVIN KLEIN 205W39NYC Global Advertising Campaign

Image not foundFALL 2017 CALVIN KLEIN 205W39NYC GLOBAL ADVERTISING CAMPAIGN (Photo: © 2017 Willy Vanderperre)NEW YORK -Monday, July 24th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE: PVH], today announced the Fall 2017 CALVIN KLEIN 205W39NYC global multi-media advertising campaign. The campaign features the debut CALVIN KLEIN 205W39NYC collection by Chief Creative Officer Raf Simons.

Shot by photographer Willy Vanderperre, the visually striking campaign presents a cast of 22 models shot against a series of billboards that feature images from last season’s CALVIN KLEIN: American Classics campaign. The billboards of the previous campaign – which include works by artist Andy Warhol – were erected in the California desert in the days leading up to the shoot. The campaign is a study in art and artifice, of the real and the imagined, the mannered world of high fashion combined with a sense of the everyday. Ultimately, the campaign explores the cinematic and romantic outsider’s view of America, something of a dream world that has become concrete for Chief Creative Officer Raf Simons and Creative Director Pieter Mulier.

With over 850 million impressions planned across 22 global markets with an integrated media mix, this campaign will deliver on the continued evolution of CALVIN KLEIN under Simons. The brand will be featured extensively in fashion and lifestyle publications around the world during September’s fashion-focused issues. The re-appropriation of the successful American Classics campaign will come to life in large format and high impact outdoor in key locations such as New York, Paris, Brussels, China, Korea and Hong Kong.

The Fall 2017 CALVIN KLEIN 205W39NYC collection featured in the campaign is a mix of marching band uniforms, plastic coated protection, power broker tailoring, antique handcrafted quilting, workwear, and western wear. The line also includes the introduction of CALVIN KLEIN JEANS ESTABLISHED 1978, a new designer denim line that will be housed under the CALVIN KLEIN 205W39NYC business. Pieces throughout the line are emblazoned with an exclusive patch that features a silhouette inspired by the iconic Richard Avedon image taken of actress Brooke Shields for Calvin Klein Jeans in 1981. The memorable campaign image debuted shortly after the launch of the Calvin Klein Jeans brand and the concept of designer jeans – in this way, CALVIN KLEIN JEANS ESTABLISHED 1978 celebrates both the history of the brand and its future.

Calvin Klein is a global lifestyle brand that exemplifies bold, progressive ideals and a seductive, and often minimal, aesthetic. We seek to thrill and inspire our audience while using provocative imagery and striking designs to ignite the senses.

Founded in 1968 by Calvin Klein and his business partner Barry Schwartz, we have built our reputation as a leader in American fashion through our clean aesthetic and innovative designs. Global retail sales of Calvin Klein brand products exceeded $8 billion in 2015 and were distributed in [over] 110 countries. Calvin Klein employs over 10,000 associates globally. We were acquired by PVH Corp. in 2003.

With a history going back over 130 years, PVH Corp. has excelled at growing brands and businesses with rich American heritages, becoming one of the largest apparel companies in the world. We have over 30,000 associates operating in over 40 countries with over $8 billion in revenues. We own the iconic Calvin Klein, Tommy Hilfiger, Van Heusen, IZOD, ARROW, Speedo*, Warner’s and Olga brands and market a variety of goods under these and other nationally and internationally known owned and licensed brands.

*The Speedo brand is licensed for North America and the Caribbean in perpetuity from Speedo International, Ltd.

EDITORIAL CREDIT: CALVIN KLEIN 205W39NYC

IMAGE CREDITS: © 2017 Willy Vanderperre

SOCIAL MEDIA: facebook.com/calvinklein; calvinklein.tumblr.com; google.com/+calvinklein; youtube.com/calvinklein; twitter.com/calvinklein; instagram.com/calvinklein; pinterest.com/calvinklein
snapchat: calvinklein
brand handle: @calvinklein



Contacts

Calvin Klein, Inc.
Alexandra Wagner, 212-292-9794
SVP, Corporate Communications
alexandrawagner@ck.com
or
Amanda Peña, 212-292-9223
Director, Corporate Communications
amandapena@ck.com

Permalink : http://www.me-newswire.net/news/4299/en

Monday, July 24, 2017

Ultra HD Gains Momentum in the US with 30 Pay TV Providers Testing 4K Delivery on SES's Platform


Nine more US cable and IPTV operators have initiated Ultra HD trials using SES’s pre-packaged solution

LUXEMBOURG-Monday, July 24th 2017 [ ME NewsWire ]

(BUSINESS WIRE)-- With an additional nine TV operators joining SES’s Ultra HD trials, a total of 30 US Pay TV providers, with a combined audience of more than 10 million subscribers, are now testing SES’s 4K content delivery platform across their distribution networks.

The latest wave of Pay TV system operators to ink Ultra HD trial agreements with SES includes:

    Alliance Communications, an Internet, phone and cable TV operator serving subscribers in South Dakota and Minnesota;
    Cincinnati Bell, a leading telco in Ohio, Indiana and Kentucky;
    Douglas County Community Network, an ultra-high-speed broadband and IPTV provider in the state of Washington;
    Hotwire, a national telecom provider;
    Midco, a regional provider of triple play services in North Dakota, South Dakota, Minnesota, Wisconsin, and Kansas;
    Midwest Video Solutions (MVS), a multi-service provider in Wisconsin, Minnesota and Illinois;
    Oneida Telephone Exchange, a triple play service provider operating in Oneida, Illinois and Rio, Illinois;
    Skitter TV, a national IPTV systems innovator; and
    South Dakota Networks (SDN), an enabler of IPTV for 19 telcos in South Dakota.

Among the 30 operators on SES’s 4K platform, three have already initiated commercial linear Ultra HD services in subscriber homes via SES’s end-to-end solution: Marquette-Adams Communications in Wisconsin, Highlands Cable Group in North Carolina, and, most recently, EPB Fiber Optics in Chattanooga, Tennessee.

SES’s all-in-one Ultra HD platform combines satellite distribution services, reception gear, and the world’s largest 4K Ultra HD channel line-up, featuring Fashion One 4K, Travelxp 4K, 4KUNIVERSE, NASA TV UHD, INSIGHT TV, UHD1, C4K360, Funbox UHD, Nature Relaxation 4K and SES’s UHD demonstration channel.

“The turnkey SES Ultra HD platform is home to some of the largest and smallest cable and IPTV providers in the region, who are leveraging the scalability and reliability of satellite to differentiate themselves in a competitive market with the ultimate television experience,” said Steve Corda, Vice President of Business Development at SES Video, SES’s global media business unit. “Momentum continues to build as SES accelerates the delivery and commercial availability of Ultra HD services throughout North America, and we expect more cable and IPTV providers to join the trio of operators who have already launched their commercial Ultra HD services using our platform.”

“Hotwire is well positioned to be the first to market with exciting new Ultra HD services later this year, as a result of our Ultra HD trials with SES,” said Jonathan Bullock, Vice President of Corporate Development and Government at Hotwire Communications. “The SES Ultra HD platform is easy and fast to deploy on our all-fiber network, allowing us to provide the best 4K channel line-up virtually overnight.”

“SES’s Ultra HD solution is tailor-made to meet our subscribers’ demand for the best television experience available and our strong desire to be among the first to market with the world’s leading 4K offering,” said Michael Agostinelli, CEO at Skitter. “Skitter now has a clear competitive advantage as we make an exciting leap toward a commercial launch of Ultra HD services in our customers’ homes.”

Follow us on:

Twitter: https://twitter.com/SES_Satellites

LinkedIn: https://www.linkedin.com/company/ses

Facebook: https://www.facebook.com/SES.Satellites

YouTube: http://www.youtube.com/SESVideoChannel

Blog: https://www.ses.com/news/blogs

Media Gallery: https://www.ses.com/media-gallery

SES White papers are available under: https://www.ses.com/news/whitepapers

About SES

SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in two key business units; SES Video and SES Networks. The company provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions. SES’s portfolio includes the ASTRA satellite system, which has the largest Direct-to-Home (DTH) television reach in Europe, O3b Networks, a global managed data communications service provider, and MX1, a leading media service provider that offers a full suite of innovative digital video and media services. SES is listed on the Euronext Paris and Luxembourg Stock Exchange (Euronext Paris:SESG) (LuxX:SESG). Further information available at: www.ses.com



Contacts

SES
Markus Payer
Corporate Communications and Global PR
Tel. +352 710 725 500
Markus.Payer@ses.com



Permalink : http://me-newswire.net/news/4298/en



Johnson & Johnson Announces Encouraging First-in-Human Clinical Data for Investigational HIV Preventive Vaccine

Image not foundPARIS, France -Monday, July 24th 2017 [ ME NewsWire ]
In Phase 1/2a APPROACH study, HIV-1 antibody response observed in all healthy volunteers
Mosaic-based vaccine regimen is designed to elicit an immune response against a wide variety of HIV subtypes prevalent worldwide
Positive clinical and preclinical results inform selection of lead mosaic HIV vaccine regimen for further evaluation in Phase 2b proof-of-concept study
(BUSINESS WIRE)-- Johnson & Johnson today announced encouraging first-in-human clinical data for an investigational HIV-1 vaccine regimen in development at its Janssen Pharmaceutical Companies. In an oral presentation of the early stage Phase 1/2a APPROACH study at the 9th IAS Conference on HIV Science (IAS 2017), the “mosaic”-based vaccine regimen from Janssen Vaccines & Prevention B.V. (Janssen) appeared to be well-tolerated and elicited HIV-1 antibody responses in 100% of healthy volunteers (n=393).
“Finding a preventive vaccine has proven to be one of the biggest scientific challenges in the 35-year quest to end the HIV pandemic. A successful preventive vaccine for HIV will need to provide broad protection against a wide range of viral strains,” said Professor Dan Barouch, Harvard Medical School, Director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center and a key collaborator for APPROACH. “These promising, early-stage results suggest that these vaccines utilizing mosaic immunogens should be evaluated further for their potential ability to achieve this historic goal.”
Significant progress has been made in the global battle against HIV/AIDS, including the development of critical antiretroviral treatments and HIV prevention tools, yet the disease remains one of the greatest global health threats of our time. An estimated 37 million people are currently living with HIV-1 globally, and nearly 2 million people become newly infected each year. An effective HIV vaccine is elusive due to the unique properties of the virus – including its genetic diversity and ability to mutate rapidly.
Mosaic-based vaccines contain immunogens created using genes from different HIV subtypes responsible for HIV-1 infections worldwide. These immunogens are delivered through viral vectors, including Janssen’s AdVac® technology based on adenovirus serotype 26 (Ad26). The viral vectors are combined with other components such as soluble proteins to form mosaic-based prime-boost vaccine regimens that first prime and then boost the immune system, with the aim of producing stronger and longer-lasting immunity to HIV.
Paul Stoffels, M.D., Chief Scientific Officer, Johnson & Johnson said, “In recent years, a new optimism has emerged that we will find an effective HIV vaccine in our lifetime. The results from today’s study add to that belief and we look forward to advancing to the next stage of clinical development as quickly as possible.”
In pre-clinical studies, regimens incorporating mosaic vaccines demonstrated protection against infection with an HIV-like virus. The most effective prime-boost regimen in these studies reduced the per-exposure risk of infection by 94 percent and resulted in 66 percent complete protection after six exposures.
Based on immunologic responses observed in APPROACH, as well as protection observed in pre-clinical studies, a lead HIV-1 vaccine regimen comprising Janssen’s Ad26 mosaic candidate and the Clade C gp140 soluble protein has been selected as the basis for further evaluation in a potential Phase 2b proof-of-concept efficacy study. Should this study move forward, Janssen and its global partners anticipate initiating this investigation in southern African countries in late 2017 or early 2018.
About the APPROACH Study
APPROACH (HIV-V-A004/NCT02315703) is a multi-center, randomized, parallel-group, placebo-controlled, double-blind Phase 1/2a study in 393 healthy HIV-uninfected adults in the US, Rwanda, Uganda, South Africa and Thailand. It is evaluating the safety, tolerability and immunogenicity of various mosaic-based, prime-boost vaccine regimens for HIV-1. These vaccine regimens contain two prime doses of the mosaic viral vector Ad26.Mos.HIV and two boosts of either Ad26.Mos.HIV, MVA-Mosaic and/or different doses of the soluble protein Clade C gp140 adjuvanted with aluminum phosphate. Vaccination schedules have been completed for all study participants and 12-month follow-up after the 4th dose is underway.
Results presented at IAS 2017 suggest that all vaccine regimens appeared to be well-tolerated. Injection site pain, headache and fatigue were the most common reported adverse events. The primary analysis post 3rd vaccination showed that most active vaccine regimens elicited antibody responses in 100% of study participants. Antibody titers against autologous Clade C and heterologous cross-clade Env antigens increased in groups boosted with gp140 protein, irrespective of vector. After the 4th vaccination, humoral and cellular responses further increased.
The APPROACH study was sponsored by Janssen with support from partner organizations including Beth Israel Deaconess Medical Center (BIDMC); the United States Military HIV Research Program (MHRP) at the Walter Reed Army Institute of Research (WRAIR), with the Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF); the National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH); the Ragon Institute; the International AIDS Vaccine Initiative (IAVI); and the HIV Vaccine Trials Network (HVTN).
About Janssen’s HIV Preventive Vaccine
Janssen’s HIV-1 AdVac®-based vaccine regimen, along with the company’s investigational Ebola and inactivated polio vaccine candidates, utilize Janssen’s PER.C6® production cell line technology, which has the potential to reduce costs by increasing vaccine production at lower reactor volume.
Since 2005, Janssen Vaccines & Prevention B.V. has been participating in the NIH-supported Integrated Preclinical/Clinical AIDS Vaccine Development (IPCAVD) program under grants AI066305, AI078526 and AI096040. Janssen’s HIV vaccine program has also received funding from the United States Military HIV Research Program and the Ragon Institute.
Please visit www.jnj.com/HIV for further details on the breadth of HIV science being presented by Johnson & Johnson companies and its partners.
About Johnson & Johnson
Caring for the world one person at a time inspires and unites the people of Johnson & Johnson. We embrace research and science – bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 126,400 employees at more than 230 Johnson & Johnson operating companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
About the Janssen Pharmaceutical Companies
At the Janssen Pharmaceutical Companies of Johnson & Johnson, we are working to create a world without disease. Transforming lives by finding new and better ways to prevent, intercept, treat and cure disease inspires us. We bring together the best minds and pursue the most promising science. We are Janssen. We collaborate with the world for the health of everyone in it. Learn more at www.janssen.com. Follow us at @JanssenGlobal.
Cautions Concerning Forward-Looking Statements
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995, regarding development of a potential preventive vaccine for HIV. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Janssen Vaccines & Prevention B.V. and/or Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory action; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 1, 2017, including under “Item 1A. Risk Factors,” its most recently filed Quarterly Report on Form 10-Q, including under the caption “Cautionary Note Regarding Forward-Looking Statements,” and the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.govwww.jnj.com or on request from Johnson & Johnson. None of the Janssen Pharmaceutical Companies or Johnson & Johnson undertakes to update any forward-looking statement as a result of new information or future events or developments.

Contacts
Johnson & Johnson
MEDIA CONTACTS:
Ronan Collins
+47 488 42500
Rcollin5@its.jnj.com
or
Katie Buckley
+ 44 797 195 6179
Kbuckle8@its.jnj.com
or
Gavin Hart
+1 917 686 9221
Ghart9@its.jnj.com
or
INVESTOR RELATIONS:
Lesley Fishman
+1 732 524 3922
or
Joseph J. Wolk
+ 1 732 524 1142

People with idiopathic pulmonary fibrosis (IPF) reveal high burden of disease in new survey

INGELHEIM, Germany -Monday, July 24th 2017 [ ME NewsWire ]
Image not found• 61% of IPF patients are worried or extremely worried about experiencing an acute IPF exacerbation1
• Survey underlines the importance of appropriate support and coping mechanisms for patients living with IPF1
• Healthcare teams emphasise the need of a strong support network and multi-disciplinary care for people with IPF
(BUSINESS WIRE)-- New results from a global survey supported by Boehringer Ingelheim1 reveal the emotional and practical challenges facing people with idiopathic pulmonary fibrosis (IPF). Patients are impacted by feelings of anxiety, fear, uncertainty and hopelessness, as well as a restriction in everyday activities.1 However, a range of both medical and non-medical support is available to help them cope with their disease.2
The survey uncovers patient concerns about the irreversible progression of their disease. Patients are especially worried over acute IPF exacerbations - a rapid deterioration of symptoms within days or weeks, which can significantly reduce chances of survival and lead to death within a few months.3 More than 150 patients across nine countries were interviewed. 61% of respondents report that they are worried (39%) or extremely worried (22%) about experiencing an acute IPF exacerbation.1
Patients also highlighted the impact of the physical limitations caused by the disease, the importance of knowing how long they will be able to be active and continue with their hobbies and accepting and learning how to live with the condition.1
Dr. Marlies Wijsenbeek, pulmonologist, Erasmus MC, The Netherlands commented, “We know a lot about the physiological changes that occur in IPF but surveys like this help us to better understand the psychological burden. While medical care is available to help slow the progression of IPF right after diagnosis, it is also crucial that patients are given emotional support from the earliest stage possible to help minimise anxiety associated with the disease. In daily practice we need to continuously remind ourselves that we are not just treating lungs, we are treating people.”
Support for patients dealing with the challenge of IPF goes beyond drug therapy and can include supply of additional oxygen when needed and pulmonary rehabilitation programmes, including advice on the diet and exercise plan most appropriate to an individual patient’s disease and medication.2 Patients can benefit from speaking with their physician about the challenges they face, however further emotional and practical support can also be gained from the wider team of healthcare professionals, such as nursing support, social workers, psychologists and physiotherapists, as well as family, friends and patient support groups.
Marianne Seiter, nurse specialised in interstitial lung diseases, Thoraxklinik, Universitätsklinikum Heidelberg, Germany, said, “A strong support network is vital for patients with IPF to help address the full impact of the disease. Nurses, and other members of the multi-disciplinary team, can help patients take a pro-active approach to managing their condition through a range of care options. With appropriate support we can work together to help patients maintain the best quality of life possible.”
Stephen Jones, an IPF patient from UK said, “As IPF patients, we know our lungs will deteriorate and it will be hard to breathe, but we don’t know when that is going to happen. This can create a lot of worry and anxiety. It is important that we make the very best of the wide range of available support from healthcare professionals and patient groups, as well as close family and friends.”
Improving the wellbeing of people with fibrosing lung diseases such as IPF is a priority for Boehringer Ingelheim. As part of this commitment, Boehringer Ingelheim is currently enrolling patients to participate in further clinical trials investigating the efficacy of nintedanib in treating interstitial lung disease associated with conditions other than IPF, including people with systemic sclerosis who have also developed interstitial lung disease (SSc-ILD) and people with other progressive fibrosing interstitial lung diseases (PF-ILD).*
*Nintedanib is currently not approved for use in SSc ILD or PF ILD and its safety and efficacy has not yet been fully established.

Please click on the link below for ‘Notes to Editors’ and ‘References’:
http://www.boehringer-ingelheim.com/press-release/ipf_survey_burden_of_disease
Intended audiences:
This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business.
Contacts
Boehringer Ingelheim
Corporate Communications
Media + PR
Dr. Kristin Jakobs
Phone: +49 6132 – 77 144553
Fax: +49 6132 – 77 6601
Email: press@boehringeringelheim.com

Permalink : http://me-newswire.net/news/4294/en